NCT05267587
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have MRI evidence of 1 or more brain metastases no less than 10 mm and no greater than 60 mm in maximum diameter; Patients must have brain metastases deemed surgically resectable by a neurosurgeon
Exclusions: Patients with any prior cranial radiotherapy targeting the index lesion; Patients with prior whole brain radiation within the previous three months; Patients with symptomatic brain metastases not well controlled with steroid medication; Patients with widespread leptomeningeal metastasis
https://ClinicalTrials.gov/show/NCT05267587